The CD19/CD22-directed bispecific chimeric antigen receptor (CAR) T-cell therapy, known as CAR2219, has demonstrated remarkably high efficacy in patients with relapsed or refractory large B-cell lymphoma (LBCL). A recent phase 2 clinical trial presented at the 2025 European Society for Medical Oncology (ESMO) Congress reported a 100% overall response rate (ORR) and a 67.7% complete response (CR) rate at a median follow-up of 4.2 months, highlighting significant promise in this difficult-to-treat population.
This prospective, single-arm, single-center trial enrolled 31 patients who were infused with CAR2219, a novel bispecific CAR T-cell construct targeting both CD19 and CD22 antigens expressed on B-cell lymphoma cells. Early responses were especially notable: at just four weeks post-infusion, 93.5% of patients had responded with 61.3% achieving complete remission. The therapy also showed broad efficacy across multiple prespecified subgroups, although CR rates were lower in men, patients with bulky tumors (≥5 cm), and those with double-expressor or double-hit lymphoma phenotypes.
Scientific and Clinical Rationale for CAR2219
While CAR T-cell therapies targeting CD19 have improved outcomes in LBCL, limitations remain, especially in patients with relapsed or refractory disease. A 2023 analysis of more than 41,000 diffuse large B-cell lymphoma (DLBCL) patients from the US SEER database showed improved overall survival after CAR T-cell approvals, yet median event-free survival remained under six months in historical data from the pivotal ZUMA-1 trial for axicabtagene ciloleucel (Yescarta), indicating the need for enhanced therapies.
CAR2219 innovates by incorporating two single-chain variable fragments targeting CD19 and CD22, potentially overcoming tumor escape mechanisms associated with loss or downregulation of a single antigen. This dual targeting aims to reduce relapse rates and improve durable remissions. The therapeutic construct also includes a truncated EGFR marker facilitating monitoring of CAR T-cell expression and allowing antibody-mediated clearance if severe adverse events occur.
Study Design and Patient Population
The phase 2 trial involved leukapheresis to collect patients’ peripheral blood mononuclear cells, followed by lymphodepletion using cyclophosphamide and fludarabine over three days. Subsequently, patients received CAR2219 infusion dosed at 2 million cells/kg. Some patients received bridging therapy, including mitoxantrone liposome combined with dexamethasone and polatuzumab vedotin, to control disease before CAR T-cell administration. Maintenance treatments such as PD-1 inhibitors could be introduced from one month post-infusion for responders.
The enrolled population primarily consisted of heavily pretreated patients with advanced-stage disease (stage IV in 74%), refractory status (74%), and multiple poor prognostic markers like elevated lactate dehydrogenase, extranodal involvement, and double-expressor/double-hit lymphoma biology. This underscores the challenging clinical context in which CAR2219 demonstrated high efficacy.
Efficacy and Immune Monitoring
At the clinical cutoff, median progression-free survival (PFS) and overall survival (OS) were not reached, with estimated six-month PFS and OS rates of 83% and 87.1%, respectively. CAR T-cell expansion peaked typically between days 10 and 14 post-infusion and was detectable in most patients beyond three months, correlating with sustained clinical responses. Interleukin-6 (IL-6) levels, a marker of immune activation, peaked within the first week, sometimes necessitating intervention with tocilizumab.
Notably, a heavily pretreated patient with prior PD-1 inhibitor failure initially progressed but subsequently achieved durable remission after retreatment with PD-1 blockade, coinciding with persistent CAR T-cell presence. This case highlights potential synergy between CAR T therapy and checkpoint inhibitors as well as phenomena related to T-cell exhaustion that could inform future combinational strategies.
Safety Profile
Safety data indicated CAR2219 was generally well tolerated. The most common adverse event was cytokine release syndrome (CRS), occurring in 74% of patients but limited to grade 1 or 2 severity, with no instances of severe (grade 3 or higher) CRS. Immune effector cell–associated neurotoxicity syndrome (ICANS) was rare, with only one grade 3 case that resolved following intensive supportive care including steroids and plasma exchange. Hematologic toxicities such as neutropenia and thrombocytopenia were frequent but manageable.
Context in the CAR T-Cell Therapy Landscape
These findings add to a growing body of evidence seeking to optimize CAR T-cell approaches in lymphoma by incorporating dual antigen targeting to minimize tumor escape and improve response durability. The encouraging efficacy and tolerability profile of CAR2219 aligns with technological advancements in CAR design coupled with improved preconditioning and supportive care protocols.
The trial was funded by the National Natural Science Foundation of China and major national science and technology programs, underscoring global collaborative efforts to enhance immunotherapies against hematologic malignancies.
Broader Market and Technological Implications
The development of CAR2219 comes amid notable advancements in biotech and immunotherapy sectors, where innovation is accelerating rapidly. From a technology infrastructure standpoint, the biotech industry increasingly leverages advanced computational methods, including AI-driven drug discovery and biomarker identification, to refine CAR T-cell constructs and patient selection, reflecting broader digital transformation trends in life sciences.
As funding grows and regulatory frameworks mature, the market for cell therapies is expected to expand substantially. The precision and dual specificity of CAR2219 highlight a cutting-edge clinical execution of bioengineering, merging molecular targeting and immunologic principles to address complex cancer biology.
For readers tracking innovation at the intersection of advanced therapeutics and digital biotech, CAR2219 exemplifies how engineered immune cells are reshaping oncology care by integrating sophisticated molecular designs with evolving clinical protocols. Read more on Globally Pulse Technology about how these therapies relate to broader trends in artificial intelligence, genomics, and healthcare digitalization.
